RU2014106364A - Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2 - Google Patents
Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2 Download PDFInfo
- Publication number
- RU2014106364A RU2014106364A RU2014106364/04A RU2014106364A RU2014106364A RU 2014106364 A RU2014106364 A RU 2014106364A RU 2014106364/04 A RU2014106364/04 A RU 2014106364/04A RU 2014106364 A RU2014106364 A RU 2014106364A RU 2014106364 A RU2014106364 A RU 2014106364A
- Authority
- RU
- Russia
- Prior art keywords
- ylidine
- amine
- imidazolidin
- compound according
- compound
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims abstract 14
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 7
- 239000000460 chlorine Substances 0.000 claims abstract 7
- SVNCRRZKBNSMIV-UHFFFAOYSA-N 3-Aminoquinoline Chemical compound C1=CC=CC2=CC(N)=CN=C21 SVNCRRZKBNSMIV-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- 150000002431 hydrogen Chemical group 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 6
- LYFHAPSWVAJTFJ-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)quinolin-3-amine Chemical compound N1CCN=C1NC1=CN=C(C=CC=C2)C2=C1 LYFHAPSWVAJTFJ-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000001246 bromo group Chemical group Br* 0.000 claims abstract 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical class 0.000 claims abstract 4
- QAHXHCJENQEPHB-UHFFFAOYSA-N pyrido[2,3-b]pyrazin-7-amine Chemical compound N1=CC=NC2=CC(N)=CN=C21 QAHXHCJENQEPHB-UHFFFAOYSA-N 0.000 claims abstract 3
- SQTLUXJWUCHKMT-UHFFFAOYSA-N 4-bromo-n,n-diphenylaniline Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SQTLUXJWUCHKMT-UHFFFAOYSA-N 0.000 claims abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 208000033830 Hot Flashes Diseases 0.000 claims 2
- 206010060800 Hot flush Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 240000005926 Hamelia patens Species 0.000 claims 1
- 208000014692 Lyell syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000003493 Rhinophyma Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010054786 Skin burning sensation Diseases 0.000 claims 1
- 244000061456 Solanum tuberosum Species 0.000 claims 1
- 235000002595 Solanum tuberosum Nutrition 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000012015 potatoes Nutrition 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 0 *c(c(*C=C*1)c1nc1)c1N=C1NCCN1 Chemical compound *c(c(*C=C*1)c1nc1)c1N=C1NCCN1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161511298P | 2011-07-25 | 2011-07-25 | |
| US61/511,298 | 2011-07-25 | ||
| PCT/US2012/047570 WO2013016178A1 (en) | 2011-07-25 | 2012-07-20 | N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014106364A true RU2014106364A (ru) | 2015-08-27 |
Family
ID=46582084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014106364/04A RU2014106364A (ru) | 2011-07-25 | 2012-07-20 | Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8815861B2 (enExample) |
| EP (1) | EP2736902A1 (enExample) |
| JP (1) | JP6031719B2 (enExample) |
| KR (1) | KR20140062471A (enExample) |
| CN (1) | CN103827107A (enExample) |
| AU (1) | AU2012287164A1 (enExample) |
| BR (1) | BR112014001938A2 (enExample) |
| CA (1) | CA2843251A1 (enExample) |
| HK (1) | HK1198762A1 (enExample) |
| RU (1) | RU2014106364A (enExample) |
| WO (1) | WO2013016178A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2791469C2 (ru) * | 2017-12-01 | 2023-03-09 | Орион Корпорейшн | Способ получения 2-(5-метоксиизохроман-1-ил)-4,5-дигидро-1h-имидазола и его гидросульфата |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8941159B2 (en) | 2013-01-30 | 2015-01-27 | Omnivision Technologies, Inc. | Color filter including clear pixel and hard mask |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB889282A (en) * | 1957-05-07 | 1962-02-14 | Air Reduction | Preparation of hexafluorodiethyl ether and medicinal compositions containing it |
| BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| AU688380B2 (en) * | 1993-10-13 | 1998-03-12 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| CN1046718C (zh) * | 1993-12-17 | 1999-11-24 | 普罗克特和甘保尔公司 | 用作α－2肾上腺素能受体兴奋剂的6－(2－亚咪唑烷基氨基)喹啉化合物 |
| DE69425334T2 (de) * | 1993-12-17 | 2001-02-08 | The Procter & Gamble Company, Cincinnati | 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten |
| US5576437A (en) * | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| AU704972B2 (en) | 1994-08-04 | 1999-05-13 | H. Lundbeck A/S | Novel benzimidazole derivatives |
| AU715350B2 (en) * | 1995-05-12 | 2000-01-20 | Allergan, Inc. | Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects |
| US6087361A (en) * | 1995-05-12 | 2000-07-11 | Allergan Sales, Inc. | Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects |
| US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| WO2011044229A1 (en) * | 2009-10-06 | 2011-04-14 | Allergan, Inc. | 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators |
-
2012
- 2012-07-20 RU RU2014106364/04A patent/RU2014106364A/ru not_active Application Discontinuation
- 2012-07-20 WO PCT/US2012/047570 patent/WO2013016178A1/en not_active Ceased
- 2012-07-20 HK HK14112237.2A patent/HK1198762A1/xx unknown
- 2012-07-20 US US13/554,546 patent/US8815861B2/en active Active
- 2012-07-20 KR KR1020147004720A patent/KR20140062471A/ko not_active Withdrawn
- 2012-07-20 CN CN201280046305.5A patent/CN103827107A/zh active Pending
- 2012-07-20 EP EP12740272.5A patent/EP2736902A1/en not_active Withdrawn
- 2012-07-20 AU AU2012287164A patent/AU2012287164A1/en not_active Abandoned
- 2012-07-20 BR BR112014001938A patent/BR112014001938A2/pt not_active IP Right Cessation
- 2012-07-20 JP JP2014522900A patent/JP6031719B2/ja not_active Expired - Fee Related
- 2012-07-20 CA CA2843251A patent/CA2843251A1/en not_active Abandoned
-
2014
- 2014-07-15 US US14/332,110 patent/US9199989B2/en active Active
-
2015
- 2015-10-28 US US14/925,065 patent/US20160045489A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2791469C2 (ru) * | 2017-12-01 | 2023-03-09 | Орион Корпорейшн | Способ получения 2-(5-метоксиизохроман-1-ил)-4,5-дигидро-1h-имидазола и его гидросульфата |
Also Published As
| Publication number | Publication date |
|---|---|
| US9199989B2 (en) | 2015-12-01 |
| JP6031719B2 (ja) | 2016-11-24 |
| US20160045489A1 (en) | 2016-02-18 |
| US8815861B2 (en) | 2014-08-26 |
| CA2843251A1 (en) | 2013-01-31 |
| KR20140062471A (ko) | 2014-05-23 |
| HK1198762A1 (en) | 2015-06-05 |
| WO2013016178A1 (en) | 2013-01-31 |
| EP2736902A1 (en) | 2014-06-04 |
| AU2012287164A1 (en) | 2014-02-20 |
| US20140329852A1 (en) | 2014-11-06 |
| CN103827107A (zh) | 2014-05-28 |
| US20130029994A1 (en) | 2013-01-31 |
| JP2014521647A (ja) | 2014-08-28 |
| BR112014001938A2 (pt) | 2017-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5165242B2 (ja) | 疼痛およびα２アドレナリン受容体が関与する他の状態の処置のための方法および組成物 | |
| DK2953948T3 (en) | FLUORINATED INTEGRIN ANTAGONISTS | |
| ES2374336T3 (es) | Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo. | |
| JP2008505173A (ja) | 痛みおよび他のα２アドレナリン作動性仲介状態を処置するための方法および組成物 | |
| RU2012134639A (ru) | Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза | |
| JP2011042668A5 (enExample) | ||
| JP6466504B2 (ja) | 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| JP5875585B2 (ja) | 緑内障および高眼圧症の処置のためのアデノシンａ１アゴニスト | |
| US10485786B2 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| TW201927298A (zh) | 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥 | |
| RU2014106367A (ru) | N-(ИМИДАЗОЛИДИН-2-ИЛИДЕН)-ГЕТЕРОЦИКЛОПЕНТА[b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ | |
| RU2019100424A (ru) | Композиции для лечения и профилактики вазомоторных симптомов | |
| JP2014521642A5 (enExample) | ||
| FI3519050T3 (fi) | Koostumuksia silmätautien hoitamiseksi | |
| JP2014521647A5 (enExample) | ||
| RU2014106328A (ru) | Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки | |
| WO2019132782A1 (en) | Compounds for treating eye diseases and methods thereof | |
| JP6513021B2 (ja) | フェニルイミダゾール誘導体、および炎症性疾患などの治療薬若しくは予防薬 | |
| JP2009517375A (ja) | 眼の疾患の治療 | |
| CA3018375C (en) | Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages | |
| RU2014125518A (ru) | Фармацевтические композиции, содержащие 7-(1н-имидазол-4-илметил)-5,6,7,8-тетрагидро-хинолин для ретинальной нейропротекции | |
| RU2021139630A (ru) | Композиции для лечения и профилактики вазомоторных симптомов | |
| WO2014143591A1 (en) | Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170616 |